Elanco Logo

IncrexxaTM (tulathromycin injection)

Increxxa logo

IncrexxaTM (tulathromycin injection)

For the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae (APP), Pasteurella multocida (PM), Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae (M. hyo). For the control of SRD associated with APP, PM, and M. hyo in groups of pigs where SRD has been diagnosed.

Find your balance

  • Proven.
  • Rapid.*
  • Backed.

Tulathromycin Mode of Action

A balance of speed and persistence. By quickly targeting and rapidly circulating at the site of infection, with its long half-life, IncrexxaTM (tulathromycin injection) controls SRD early in the disease process, providing pigs more time to mount an effective SRD defense.1,2*

Rapid Absorption*


Extended Distribution*


Slow Elimination*


Prolonged Concentration*


Your Tulathromycin Choice

  • Balancing whole herd health with individual pig solutions. Combat SRD with Increxxa’s industry-proven molecule.
  • Controlling disease challenges requires a balanced approach to management practices, biosecurity and herd health choices. Elanco’s SRD portfolio — supported by our industry-leading technical team and unwavering quality assurance — offers you even more choices to find the right solution for your challenge.

Increxxa logo

Increxxa Product Label

Read the full label for important use and safety information.

Download Label

Get Full Value from start to finish

Our portfolio offers solutions that manage disease challenges and mitigate mortality to optimize health.

Swine Intestinal Integrity

Intestinal Integrity

Elanco offers feed, water-soluble and injectable intestinal integrity solutions.

See the Portfolio
Swine Respiratory Health

Respiratory Health

Managing both enteric and respiratory health challenges are critical to your herd's success.

See the Portfolio

The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions.

INDICATIONS:

  • Increxxa Injectable Solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae; and for the control of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae in groups of pigs where SRD has been diagnosed.

DIRECTIONS FOR USE:

  • Inject intramuscularly as a single dose in the neck at a dosage of 2.5 mg/kg (0.25 mL/22 lb) BW. Do not inject more than 2.5 mL per injection site.

IMPORTANT SAFETY INFORMATION:

  • CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
  • WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS.
  • Swine intended for human consumption must not be slaughtered within 5 days from the last treatment.
  • The effects of Increxxa on porcine reproductive performance, pregnancy, and lactation have not been determined.
  • Intramuscular injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
  • Store below 25°C (77°F), with excursions up to 40°C (104°F).
  • 100 mL: Use within 2 months of first puncture and puncture a maximum of 67 times. If more than 67 punctures are anticipated, the use of multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.
  • 250 mL and 500 mL: Use within 2 months of first puncture and puncture a maximum of 100 times. If more than 100 punctures are anticipated, the use of multi-dosing equipment is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.